Fol. Biol. 2003, 49, 183-190
https://doi.org/10.14712/fb2003049050183
Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study
References
1. 1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335, 1509-1512.
< , J., Korfer, A., Franks, C. R., Poliwoda, H., Kirchner, H. (https://doi.org/10.1016/0140-6736(90)93039-R>
2. 1993) Subcutaneous recombinant interleukin-2 and α-interferon in patients with advanced renal cell carcinoma: results of a multicenter phase II study. Cancer Biother. 8, 289-300.
< , J., Kirchner, H., deMulder, P., Bodenstein, H., Oliver, T., Palmer, P. A., Franks, C. R., Poliwoda, H. (https://doi.org/10.1089/cbr.1993.8.289>
3. 1995) Multiinstitutional home-therapy trial of recombinant interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13, 497-501.
< , J., Lopez Hänninen, E., Kirchner, H., Bodenstein, H., Pfreundschuh, M., Rebmann, U., Metzner, B., Illiger, H. J., Jakse, G., Niesel, T., Scholtz, H.-J., Wilhelm, S. (https://doi.org/10.1200/JCO.1995.13.2.497>
4. 1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80, 1198-1220.
< , R. M. (https://doi.org/10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H>
5. 1997) Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br. J. Cancer 76, 541-544.
< , C., Palma, G. de., Passalacqua, R., Potenzoni, D., Ferrozzi, F., Cattabiani, M. A., Manenti, L., Borghetti, A. (https://doi.org/10.1038/bjc.1997.422>
6. 1982) Augmentation of the anti-tumour therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J. Exp. Med. 155, 968-980.
< , M. A., Greenberg, P. D., Fefer, A., Gillis, S. (https://doi.org/10.1084/jem.155.4.968>
7. 1999) Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin. Cancer Res. 5, 2374-2380.
, J. I., Gaynor, E., Martone, B. (
8. 1989) Lack of interleukin-2 (IL-2) dependent growth of TAC positive T-ALL/NHL cells is due to the expression of only low affinity receptors of IL-2. Leukemia 8, 566-571.
, K. M., Woodroofe, C., Lahm, H., Fischer, J., Falk, W. (
9. 1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol. 130, 1063-1066.
< , J. B., Sarna, G., Figlin, R., Lindner, A., Smith, R. B. (https://doi.org/10.1016/S0022-5347(17)51686-9>
10. 1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48, 7310-7313.
, P. J., Witte, R. S., Trump, D. L. (
11. 1997) Interleukin 2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J. Sci. Am. 3, S92-S97.
, R., Gitlitz, B., Franklin, J., Dorey, F., Moldawer, N., Rausch, J., Kernion, J. de., Belldegrun, A. (
12. 1992) IL-2 treatment for cancer: from biology to gene therapy. Br. J. Cancer 6, 992-998.
< , R., Guarini, A., Gansbacher, B. (https://doi.org/10.1038/bjc.1992.400>
13. 1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer 30A, 1310-1314.
< , S. D., Kramar, A., Droz, J. P. (https://doi.org/10.1016/0959-8049(94)90179-1>
14. 1991) Adjuvant therapy in renal cancer. World J. Urol. 9, 232-236.
< , M., Rubben, H. (https://doi.org/10.1007/BF00182847>
15. 1997) Does it matter whom and how you ask? Interand intra-rater agreement in the Ontario Health Survey. J. Clin. Epidemiol. 50, 127-135.
< , P. V., Feeny, D. H., Furlong, W. (https://doi.org/10.1016/S0895-4356(96)00314-9>
16. 1999) Interleukin-2 inhalation therapy in pulmonary metastases of renal cell cancer - Cologne experience. Anticancer Res. 19, 2003-2004.
, A., Neubauer, S. (
17. 1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J. Clin. Oncol. 17, 3612-3620.
< , H., Mir, T. S., Huland, E., Huland, H. (https://doi.org/10.1200/JCO.1999.17.11.3612>
18. 2001) Interleukin-2 and cancer - physiological and pharmacological uses. Folia Biol. (Praha) 47, 111-112.
, E. (
19. 1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol. 147, 344-348.
< , E., Huland, H., Heinzer, H. (https://doi.org/10.1016/S0022-5347(17)37233-6>
20. 1997) Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. Cancer J. Sci. Am. 3, S98-S105.
, E., Heinzer, H., Mir, T. S., Huland, H.(
21. 1999) Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res. 19, 2679-2683.
, E., Heinzer, H., Huland, H. (
22. 2000a) A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma. Folia Biol. (Praha) 46, 241-250.
, E., Heinzer, H., Huland, H. (
23. 2000b) Overview of interleukin-2 inhalation therapy. Cancer J. Sci. Am. 6, S104-S112.
, E., Heinzer, H., Huland, H., Yung, R. (
24. 2002) Immunotherapy for metastatic renal-cell carcinoma in Germany: a nationwide survey. Urologe A 41, 282-287.
< , E., Heinzer, H., Timm, S., Aalamian, M., Huland, H. (https://doi.org/10.1007/s00120-001-0170-2>
25. 1993) The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. 4, 275-288.
< , M., Philip, T., Palmer, P., von der Maase, H., Vinke, J., Elson, P., Franks, C. R., Selby, P. (https://doi.org/10.1089/cbr.1993.8.275>
26. 1991) The immunotherapy of human cancer with interleukin-2: present status and future directions. Cancer Invest. 9, 529-542.
< , J. E., Mertelsmann, R. (https://doi.org/10.3109/07357909109018951>
27. 1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 7, 7-20.
< , R. E., Lotze, M. T., Skibber, J. M. (https://doi.org/10.1200/JCO.1989.7.1.7>
28. 1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin. Cancer Res. 2, 1115-1122.
, J., Wilhelm, K., Kessler, M. (
29. 2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 1928-1935.
< , R. J., Mazumdar, M., Bacik, J. (https://doi.org/10.1200/JCO.2000.18.9.1928>
30. 1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540.
< , R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., Ferrara, J. (https://doi.org/10.1200/JCO.1999.17.8.2530>
31. 1997) Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma. Int. J. Urol. 4, 343-348.
< , T., Kasaoka, Y., Mitani, S., Usui, T. (https://doi.org/10.1111/j.1442-2042.1997.tb00205.x>
32. 1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur. J. Cancer Clin. Oncol. 25, S21-S28.
, S., Philip, T., Stoter, G., Fossa, S. D., Janssen, S., Iacone, A., Cleton, F. S., Eremin, O., Israel, L., Jasmin, C., Rugarli, C., von der Maasse, H. (
33. 1984) Biological response modifiers program workshop, îIn vivo-effects of IL-2î. J. Biol. Response Modif. 3, 455-532.
, R. K. (
34. 1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3, 475-480.
< , P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R., Franks, C. R. (https://doi.org/10.1093/oxfordjournals.annonc.a058239>
35. 1993) A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother. 8, 123-136.
< , P. A., Atzpodien, J., Philip, T., Negrier, S., Kirchner, H., von der Maase, H., Geertsen, P., Evers, P., Loriaux, E., Oskam, R., Roest, G., Vinke, J., Franks, C. R. (https://doi.org/10.1089/cbr.1993.8.123>
36. 1977) Renal cell cancer: natural history and results of treatment. J. Urol. 119, 722-726.
< , N. P., Lavengood, R. W. (https://doi.org/10.1016/S0022-5347(17)57611-9>
37. 2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann. Thorac. Surg. 73, 1082-1087.
< , S., Meimarakis, G., Wichmann, M., Hatz, R., Schildberg, F., Fuerst, H. (https://doi.org/10.1016/S0003-4975(01)03602-5>
38. 2001) Immunotherapy of metastatic kidney cancer. Int. J. Cancer 94, 109-120.
< , G., De Vinci, C., Lo, C. G. (https://doi.org/10.1002/ijc.1426>
39. 1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br. J. Cancer 69, 1111-1114.
< , A., Négrier, S., Cany, L., Merrouche, Y., Guillou, M. Le., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T. (https://doi.org/10.1038/bjc.1994.218>
40. 1999) Inhalation of interleukin-2 as second-line treatment: CharitÈ experience. Anticancer Res. 19, 2010-2011.
, J. (
41. 1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N. Eng. J. Med. 313, 1485-1492.
< , S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E. (https://doi.org/10.1056/NEJM198512053132327>
42. 1989) Experience with the use of highdose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
< , S. A., Lotze, M. T., Yang, J. C., Abersold, P. M., Lineham, W. M, (https://doi.org/10.1097/00000658-198910000-00008>
43. 1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913.
< , S. A., Yang, J. C., Topalian, S. L. (https://doi.org/10.1001/jama.1994.03510360033032>
44. 1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst. 80, 1451-1461.
< , J. A., Kohler, P. C., Hank, J. A. (https://doi.org/10.1093/jnci/80.18.1451>
45. 1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin. Oncol. 19, S70-S79.
, M., Wilke, H.-J., Seeber S., Schmoll, H.-J. (
46. 1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Eng. J. Med. 316, 898-905.
< , W. H., Tauerm, K. W., Yanellim, J. R., Marshall, G. D., Orr, D.W., Thurman, G. B., Oldham, R. K. (https://doi.org/10.1056/NEJM198704093161502>
47. 1996) Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol. Immunother. 42, 122-126.
< , G., Aulitzky, W. E., Lorenz, J., Huber, C., MullerQuernheim, J. (https://doi.org/10.1007/s002620050261>